Does Photofacial Treatment Cause Post-Inflammatory Hyperpigmentation?

Photorejuvenation—commonly referred to as “photofacial” or intense pulsed light (IPL) therapy—is a non-invasive cosmetic procedure widely used to improve skin tone, reduce sun damage, diminish vascular lesions, and treat mild pigmentary irregularities. A frequent concern among patients, particularly those with Fitzpatrick skin types III–V, is whether IPL treatment can induce post-inflammatory hyperpigmentation (PIH), colloquially termed “rebound darkening” or “paradoxical darkening.”

While IPL is generally safe and effective when performed by trained professionals using appropriate parameters, PIH can occur—especially in individuals with higher melanin content. This phenomenon is not unique to IPL but reflects a broader principle in dermatologic laser and light-based therapies: excessive thermal injury to melanocytes or keratinocytes may trigger melanin overproduction as part of the inflammatory cascade. Risk factors include inadequate pre-treatment sun avoidance, improper device settings (e.g., excessive fluence or inappropriate filter selection), insufficient epidermal cooling, and concurrent use of photosensitizing medications or topical agents.

Clinically, PIH typically manifests within days to weeks after treatment as diffuse or speckled brown discoloration, most commonly on the cheeks, forehead, or upper lip. It is usually transient, resolving spontaneously over several weeks to months with strict sun protection and topical depigmenting agents such as hydroquinone, tranexamic acid, or azelaic acid. In rare cases, persistent pigmentation may require adjunctive interventions including low-fluence Q-switched lasers or chemical peels.

To minimize risk, evidence-based practice emphasizes thorough patient evaluation—including skin typing, medical history review, and assessment of baseline pigmentation—alongside standardized pre- and post-procedure protocols. Patients should be counseled on rigorous broad-spectrum sunscreen use (SPF 30+, reapplied every two hours outdoors), avoidance of tanning for at least four weeks before and after treatment, and discontinuation of retinoids or exfoliants 5–7 days prior to IPL.

In summary, while photorejuvenation does not inherently “cause” skin darkening, it can unmask or exacerbate underlying pigmentary instability in susceptible individuals. When delivered appropriately and supported by diligent patient preparation and aftercare, IPL remains a well-tolerated and efficacious modality for photodamage correction—with PIH being an uncommon, preventable, and manageable adverse effect rather than an expected outcome.